# Needle Based Biopsy Gun Market

> Needle-Based Biopsy Gun Market Research Report By Type (Fully Automatic Biopsy Guns, Semi-Automatic Biopsy Guns, Manual Biopsy Guns), By End Use (Hospitals, Diagnostic Laboratories, Research Institutions, Ambulatory Surgical Centers), By Product Configuration (Single Use, Reusable), By Needle Size (Fine Gauge, Medium Gauge, Large Gauge) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.32%
- **2024:** $ 2.14 Billion
- **2025:** $ 2.3 Billion
- **2035:** $ 4.65 Billion
- **Key Players:** Becton Dickinson and Company (US), Boston Scientific Corporation (US), Medtronic plc (IE), Hologic, Inc. (US), Cook Medical Incorporated (US), Terumo Corporation (JP), Smith & Nephew plc (GB), Stryker Corporation (US), C.R. Bard, Inc. (US)

**Report ID:** MRFR/HC/36922-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** May 21, 2026

**URL:** https://www.marketresearchfuture.com/reports/needle-based-biopsy-gun-market-38903

---

## Market Summary

## **Needle-Based Biopsy Gun Market Overview**

As per MRFR analysis, the Needle Based Biopsy Gun Market Size was estimated at 2.14 (USD Billion) in 2024. The Needle Based Biopsy Gun Market Industry is expected to grow from 2.29 (USD Billion) in 2025 to 4.33 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 7.32% during the forecast period (2025 - 2034).

**Key Needle-Based Biopsy Gun Market Trends Highlighted**

The Global Market For Needle-Based Biopsy Guns that utilize needles is primarily driven by the presence of prominent factors that have a positive impact on its growth. With the increasing occurrence of patients with different cancers and other diseases that require accurate diagnosis, there is a great demand for biopsy. Many patients prefer nowadays minimally invasive procedures, which lead to shorter recovery periods and less physical pain.

In addition, the consciousness of sophisticated masses on the importance of timely treatment of disease makes the market move forward at an ever-increasing pace where patients always look for efficient services. The opportunities in the market for needle-based biopsy guns are great especially where there is continuing advancement and innovations on the medical equipment.

Again, with patients where the healthcare industry is in the transitioning phase, growth possibilities with the increasing need for advanced diagnostics. As demand for needle-based biopsy devices across a variety of healthcare providers rises, collaborations between device manufacturers and healthcare organizations may also improve the availability and uptake of these technologies in clinical settings. There has been a growing trend in recent years towards the utilization of imaging modalities such as ultrasound and CT for guidance during biopsy procedures, which is becoming more routine.

This advancement not only enhances the precision of biopsies but also improves patient safety. Moreover, the growing shift towards outpatient procedures aligns with the convenience and efficiency offered by needle-based biopsy techniques. Telemedicine's integration into healthcare systems is also influencing how patients access biopsy services, making it easier for specialists to review cases remotely. As the healthcare landscape evolves, these trends continue to emerge, guiding the trajectory of the Needle-Based Biopsy Gun Market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Needle-Based Biopsy Gun Market Drivers**

### Increasing Incidence of Cancer

One of the most significant drivers contributing to the growth of the Needle-Based Biopsy Gun Market Industry is the increasing incidence of cancer worldwide. As cancer rates continue to rise due to factors such as aging populations, lifestyle changes, and environmental influences, the demand for effective diagnostic tools, such as needle-based biopsy guns, is becoming increasingly pronounced.

These devices allow for minimally invasive sampling of tissues, which is critical in the early diagnosis and management of various types of cancer.The ability to obtain precise tissue samples significantly aids healthcare professionals in determining the best treatment options, thus positively impacting patient outcomes. As the medical community shifts its focus toward early detection and intervention in cancer cases, the adoption of advanced diagnostic equipment, including needle-based biopsy guns, is expected to escalate.

Furthermore, an increase in awareness and advocacy surrounding cancer screenings is propelling healthcare systems to implement more efficient diagnostic procedures to meet this heightened demand.As healthcare providers strive to utilize technologies that enhance accuracy and reduce patient discomfort, needle-based biopsy guns will play an integral role in the cancer diagnostic landscape.

Innovations in this field, such as enhanced needle designs and automation features in biopsy guns, also contribute to the appeal of these devices. By making biopsies less painful and more precise, these advancements are further solidifying the position of needle-based biopsy guns as essential tools in oncology practices.

### Technological Advancements in Biopsy Devices

The ongoing technological advancements in biopsy devices are significantly influencing the growth of the Needle-Based Biopsy Gun Market Industry. Innovations such as improved imaging techniques, automated systems, and advanced needle designs lead to better performance and lower complications. As manufacturers integrate new technologies into needle-based biopsy guns, the efficiency and reliability of these devices enhance diagnostic capabilities.

### Rising Preference for Minimally Invasive Procedures

The rising preference for minimally invasive procedures is another critical driver for the Needle-Based Biopsy Gun Market Industry. Patients and healthcare providers alike are increasingly opting for less invasive methods due to the associated benefits, such as reduced recovery times, lower risk of complications, and less postoperative pain. As healthcare providers adapt to this trend by incorporating needle-based biopsy guns into their practice, the market is poised for growth unmatched by traditional diagnostic methods.

## **Needle-Based Biopsy Gun Market Segment Insights:**

### **Needle-Based Biopsy Gun Market Type Insights  **

The Needle-Based Biopsy Gun Market is currently experiencing steady growth, projected at a value of 1.86 USD Billion in 2023, and anticipated to grow significantly by 2032. This market can be divided into three main types: Fully Automatic Biopsy Guns, Semi-Automatic Biopsy Guns, and Manual Biopsy Guns.

The Fully Automatic Biopsy Guns held a market valuation of 0.8 USD Billion in 2023 and are forecasted to reach 1.5 USD Billion by 2032, making them a dominant player in the industry. The effectiveness, precision, and ease of operation offered by these guns make them highly favored among healthcare professionals, thereby driving their adoption and solidifying their majority holding in the market landscape.

In contrast, Semi-Automatic Biopsy Guns, with a valuation of 0.6 USD Billion in 2023, are also witnessing growth and are expected to reach 1.1 USD Billion by 2032. This segment is significant because it combines user control with automation, allowing for a balanced approach that appeals to various practitioners and settings, thus promoting its continued relevance in the marketplace.

Manual Biopsy Guns, while having a lower market value of 0.46 USD Billion in 2023 with expectations of growing to 0.9 USD Billion in 2032, represent the traditional method of biopsy collection. This type remains in use due to its simplicity and lower costs, though it lacks the efficacy of its automated counterparts.

Overall, the segmentation of the Needle-Based Biopsy Gun Market highlights a trend toward automated solutions, with the Fully Automatic Biopsy Guns segment dominating due to their enhanced accuracy and efficiency. The growing demand for advanced diagnostic techniques in the healthcare sector significantly contributes to market growth. Furthermore, innovations in technology and increasing awareness regarding early disease diagnosis serve as growth drivers for this industry.

However, challenges such as high costs associated with advanced equipment and the need for skilled professionals may pose threats to market expansion. Nevertheless, the potential opportunities for market players lie in the ongoing development of minimally invasive procedures and the increasing prevalence of diseases requiring biopsies.

As the demand for effective and precise biopsy tools continues to rise, understanding the dynamics of the Needle-Based Biopsy Gun Market segmentation becomes increasingly important for stakeholders in strategizing their market presence and addressing the needs of healthcare providers.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Needle-Based Biopsy Gun Market End-Use Insights  **

The Needle-Based Biopsy Gun Market is expected to see robust growth driven by its application across various end-use sectors. By 2023, the market was valued at 1.86 billion USD and projects substantial expansion over the ensuing years. Hospitals play a crucial role in this market, being primary sites for diagnostics and treatment. Diagnostic laboratories are significant contributors as well, primarily due to the increasing demand for accurate and rapid testing methods.

Research institutions drive innovation, enhancing the market landscape with advanced technologies in biopsy procedures.Meanwhile, ambulatory surgical centers are becoming increasingly important as they offer cost-effective solutions and convenience, attracting more patients seeking outpatient services.

The diversification across these end uses not only signifies the demand for needle-based biopsy guns but also underscores the advancements in minimally invasive procedures, addressing the needs of healthcare providers and patients alike. As the market continues to evolve, an emphasis on technological developments and strategic collaborations will present avenues for growth, making it essential to monitor the Needle-Based Biopsy Gun Market statistics for emerging trends and opportunities.

**Needle-Based Biopsy Gun Market Product Configuration Insights  **

The Needle-Based Biopsy Gun Market reached a valuation of 1.86 billion USD by 2023, highlighting a significant growth trajectory. Within this market, the Product Configuration segment is categorized into options like Single Use and Reusable models. Single-use configurations are essential due to their convenience and reduced risk of contamination, thus enhancing patient safety during procedures.

Meanwhile, Reusable devices play a pivotal role by offering cost-effective solutions, particularly in high-volume settings where sustainability is a growing concern.The Needle-Based Biopsy Gun Market revenue demonstrates a strong emphasis on these configurations, combating challenges such as adoption barriers and device reprocessing logistics.

As healthcare providers seek more effective diagnostic tools, market growth is driven by technological advancements, increased awareness of biopsy procedures, and rising incidences of diseases requiring biopsies. Furthermore, opportunities in emerging markets are expected further to influence the Needle-Based Biopsy Gun Market statistics, encouraging innovations and customization in product offerings.

### **Needle-Based Biopsy Gun Market Needle Size Insights  **

The Needle Size segment of the Needle-Based Biopsy Gun Market plays a pivotal role in the market's dynamics, reflecting diverse clinical applications and preferences. In 2023, the overall market will be valued at 1.86 billion USD, showcasing substantial growth potential as it progresses towards an estimated value of 3.5 billion USD by 2032. Within this segment, Fine Gauge needles are often preferred for their minimal discomfort and precision, making them ideal for sensitive tissue sampling.

On the other hand, Medium Gauge needles strike a balance between tissue sampling efficiency and patient comfort, while Large Gauge needles dominate in scenarios requiring deeper or larger tissue samples due to their robustness.The various needle sizes are not only essential for optimizing biopsy procedures but also significantly influence patient outcomes, demonstrating the importance of customization in the medical field.

The Needle-Based Biopsy Gun Market segmentation reflects these trends, showing increasing demand for different needle sizes driven by advancements in healthcare and a growing patient population. As the market evolves, continuous innovations will drive its expansion, positioning Needle Size as a crucial factor influencing the overall market growth.

**Needle-Based Biopsy Gun Market Regional Insights  **

The Needle-Based Biopsy Gun Market exhibited a significant valuation of 1.86 USD Billion in 2023, with expected growth reaching 3.5 USD Billion by 2032, representing a promising trajectory. Within the regional landscape, North America emerged as a dominant force, holding a substantial market value of 0.88 USD Billion in 2023, projected to rise to 1.58 USD Billion by 2032, showcasing the region's majority holding in the overall market.

Europe, with a current valuation of 0.56 USD Billion, also reflects robust growth potential, expected to reach 1.02 USD Billion in the coming years.In the Asia-Pacific region, the market was valued at 0.3 USD Billion in 2023 and is anticipated to see an increase to 0.55 USD Billion, highlighting a growing interest in advanced medical technologies.

South America and Middle-East  Africa are comparatively smaller markets, each starting at 0.06 USD Billion in 2023, with projected values of 0.1 USD Billion and 0.15 USD Billion, respectively. Despite being the least dominant, these regions present opportunities for expansion, driven by increasing healthcare advancements and rising awareness about needle-based biopsy techniques.The segmentation of the Needle-Based Biopsy Gun Market indicates a landscape of diverse growth possibilities across regions, influenced by market trends and rising demand for minimally invasive procedures.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Needle-Based Biopsy Gun Market Key Players and Competitive Insights:**

The Needle-Based Biopsy Gun Market is a crucial segment of the medical device industry, particularly within the realm of minimally invasive diagnostics. As the demand for precise and efficient diagnostic tools continues to rise, competitive dynamics are becoming increasingly pivotal in shaping this market.

Key players are focusing on advanced technologies, innovation, and strategic partnerships to establish a formidable market presence. The interplay of various factors, such as regulatory landscapes, research and development investments, and shifting healthcare trends, is setting the stage for intense competition among manufacturers. Companies are actively pursuing ways to differentiate their offerings through enhanced safety features, increased mobility, and user-friendly designs. Moreover, market players are engaging in collaborations and acquisitions to expand their capabilities and reach new demographics, further intensifying the race for market share.

Stryker, a foremost player in the Needle-Based Biopsy Gun Market, has established a strong reputation due to its commitment to quality and innovation. The company's strength lies in its extensive range of products designed specifically for precision and ease of use during biopsy procedures. By prioritizing user experience, Stryker has successfully provided healthcare professionals with reliable tools that enhance procedural efficiency and patient outcomes. The integration of advanced technologies in their needle-based biopsy guns underscores Stryker's dedication to remaining at the forefront of the industry.

Additionally, Stryker's robust distribution network allows it to maintain a significant presence in various regions, making its products readily available to a wide array of healthcare facilities. This proactive approach, focused on innovation and accessibility, solidifies Stryker's position as a leading competitor within the market.

Hologic is another significant entity in the Needle-Based Biopsy Gun Market, known for its dedication to women's health and breast cancer diagnostics. The company offers a range of needle-based biopsy solutions designed to address the specific needs of patients and healthcare providers alike. Hologic's strengths are rooted in its rigorous research and development efforts that result in cutting-edge technologies, enhancing the precision and reliability of biopsy procedures.

Their commitment to clinical education and support further empowers medical professionals in utilizing biopsy tools effectively. Hologic's initiatives to improve patient comfort and outcomes demonstrate its understanding of the industry's evolving demands. As a result, Hologic continues to expand its market reach while maintaining a firm foothold in the competitive landscape of needle-based biopsy guns.

**Key Companies in the Needle-Based Biopsy Gun Market Include:**

- Stryker
- Hologic
- Intuitive Surgical
- R. Bard
- Teleflex
- MediGel
- Philips Healthcare
- Angiodynamics
- Johnson and  Johnson
- GE Healthcare
- Boston Scientific
- Merit Medical
- Covidien
- Siemens Healthineers
- **[Medtronic](https://www.medtronic.com/en-us/healthcare-professionals/products.html)**

### Needle Based Biopsy Gun Industry Developments

- **Q2 2024: Argon Medical Devices Announces FDA Clearance of SuperCore Advantage Biopsy Instrument** Argon Medical Devices received FDA clearance for its SuperCore Advantage Biopsy Instrument, a new needle-based biopsy gun designed for soft tissue biopsies. The device aims to improve sample quality and procedural efficiency.
- **Q1 2024: INRAD, Inc. Launches New Core Needle Biopsy Device for Breast and Prostate Applications** INRAD, Inc. announced the commercial launch of its latest core needle biopsy device, targeting breast and prostate tissue sampling. The product is now available to hospitals and diagnostic centers in the United States.
- **Q2 2024: Becton Dickinson Receives CE Mark for BD UltraCore Biopsy Device** Becton Dickinson (BD) received CE Mark approval for its BD UltraCore Biopsy Device, allowing the company to market the needle-based biopsy gun in the European Union. The device is designed for minimally invasive tissue sampling.
- **Q3 2024: Hologic Announces FDA Clearance for Brevera Breast Biopsy System with Needle-Based Gun Technology** Hologic received FDA clearance for its Brevera Breast Biopsy System, which incorporates advanced needle-based gun technology for real-time tissue acquisition and imaging during breast biopsies.
- **Q2 2024: Merit Medical Launches Temno Evolution Biopsy Device in the U.S.** Merit Medical Systems announced the U.S. launch of its Temno Evolution Biopsy Device, a single-use, needle-based biopsy gun designed to enhance procedural safety and sample quality.
- **Q1 2024: Boston Scientific Acquires Devicor Medical Products, Expanding Biopsy Device Portfolio** Boston Scientific completed the acquisition of Devicor Medical Products, a manufacturer of needle-based biopsy guns and related devices, to strengthen its position in the tissue sampling market.
- **Q2 2024: ConMed Corporation Announces Partnership with MedTech Innovations for Needle Biopsy Device Distribution** ConMed Corporation entered into a distribution partnership with MedTech Innovations to expand the reach of its needle-based biopsy guns in North America and select international markets.
- **Q3 2024: Henry Schein Launches New Line of Disposable Needle Biopsy Guns** Henry Schein introduced a new line of disposable needle biopsy guns aimed at reducing infection risk and improving procedural efficiency in outpatient and hospital settings.
- **Q2 2024: Coloplast Receives FDA 510(k) Clearance for Core Needle Biopsy System** Coloplast announced it has received FDA 510(k) clearance for its new core needle biopsy system, enabling the company to market the device for soft tissue biopsies in the United States.
- **Q1 2024: Hologic Appoints New Vice President of Biopsy Device Division** Hologic announced the appointment of a new Vice President to lead its Biopsy Device Division, overseeing the development and commercialization of needle-based biopsy guns and related products.
- **Q2 2024: Becton Dickinson Opens New Manufacturing Facility for Biopsy Devices in Ireland** Becton Dickinson inaugurated a new manufacturing facility in Ireland dedicated to the production of needle-based biopsy guns, aiming to meet growing global demand for minimally invasive diagnostic tools.
- **Q3 2024: Argon Medical Devices Secures Distribution Agreement with MedSupply for Asia-Pacific Region** Argon Medical Devices signed a distribution agreement with MedSupply to expand the availability of its needle-based biopsy guns across the Asia-Pacific region.

## **Needle-Based Biopsy Gun Market Segmentation Insights**

### **Needle-Based Biopsy Gun Market Type Outlook**

- Fully Automatic Biopsy Guns
- Semi-Automatic Biopsy Guns
- [Manual Biopsy Guns](https://www.bd.com/en-us/products-and-solutions/products/product-families/mission-disposable-core-biopsy-instrument)

**Needle-Based Biopsy Gun Market End-Use Outlook**

- Hospitals
- Diagnostic Laboratories
- Research Institutions
- Ambulatory Surgical Centers

**Needle-Based Biopsy Gun Market Product Configuration Outlook**

- Single-Use
- Reusable

**Needle-Based Biopsy Gun Market Needle Size Outlook**

- Fine Gauge
- Medium Gauge
- Large Gauge

**Needle-Based Biopsy Gun Market Regional Outlook**

- North America
- Europe
- South America
- Asia-Pacific
- Middle East and Africa

## Market Drivers

### Increasing Incidence of Cancer

The Needle-Based Biopsy Gun Market is significantly impacted by the increasing incidence of cancer worldwide. As cancer rates continue to rise, the need for accurate and timely diagnosis becomes paramount. Needle-based biopsies are essential for obtaining tissue samples for histopathological examination, which is crucial for cancer diagnosis and treatment planning. Recent statistics indicate that the global cancer burden is expected to reach 29.5 million new cases by 2040, highlighting the urgent need for effective diagnostic tools. This growing demand for cancer diagnostics is likely to propel the needle-based biopsy gun market, as healthcare providers seek reliable and efficient methods for tissue sampling. Consequently, the market for needle-based biopsy guns is poised for substantial growth, driven by the increasing need for early detection and intervention in cancer care.

### Focus on Patient-Centric Designs

The Needle-Based Biopsy Gun Market is witnessing a shift towards patient-centric designs that prioritize user experience and comfort. Manufacturers are increasingly focusing on ergonomics and ease of use, which are critical for both healthcare providers and patients. Enhanced designs that reduce pain and anxiety during procedures are becoming a focal point in product development. Market analysis suggests that devices with improved patient-centric features are likely to gain a competitive edge, as they align with the growing emphasis on patient satisfaction in healthcare. Furthermore, as healthcare providers seek to improve their service offerings, the demand for innovative needle-based biopsy guns that cater to patient needs is expected to rise. This trend not only enhances the overall patient experience but also contributes to better clinical outcomes, thereby driving market growth.

### Regulatory Support and Reimbursement Policies

The Needle-Based Biopsy Gun Market is benefiting from favorable regulatory support and reimbursement policies that encourage the adoption of advanced medical technologies. Governments and health organizations are increasingly recognizing the importance of early diagnosis and treatment, leading to the establishment of supportive frameworks for innovative medical devices. Enhanced reimbursement policies for needle-based biopsy procedures are likely to incentivize healthcare providers to adopt these technologies. Market data suggests that regions with robust reimbursement structures are experiencing faster growth in the needle-based biopsy gun market. As healthcare systems continue to evolve, the alignment of regulatory support with market needs is expected to foster an environment conducive to the growth of needle-based biopsy guns, ultimately improving patient access to essential diagnostic services.

### Rising Demand for Minimally Invasive Procedures

The Needle-Based Biopsy Gun Market is significantly influenced by the rising demand for minimally invasive procedures. Patients and healthcare providers alike are increasingly favoring techniques that minimize recovery time and reduce surgical risks. Needle-based biopsies, which are less invasive compared to traditional surgical biopsies, align well with this trend. Market data indicates that the preference for outpatient procedures is on the rise, with a notable increase in the number of needle-based biopsies performed annually. This shift is expected to drive the growth of the needle-based biopsy gun market, as these devices are essential for conducting such procedures effectively. As healthcare systems continue to prioritize patient safety and comfort, the demand for needle-based biopsy guns is anticipated to expand, reflecting a broader trend towards less invasive medical interventions.

### Technological Advancements in Needle-Based Biopsy Guns

The Needle-Based Biopsy Gun Market is experiencing a surge in technological advancements that enhance the precision and efficiency of biopsy procedures. Innovations such as automated needle guidance systems and real-time imaging integration are becoming increasingly prevalent. These advancements not only improve the accuracy of tissue sampling but also reduce the risk of complications. According to recent data, the market for needle-based biopsy guns is projected to grow at a compound annual growth rate of approximately 6.5% over the next five years. This growth is largely driven by the increasing adoption of advanced technologies in healthcare settings, which aim to improve patient outcomes and streamline clinical workflows. As healthcare providers seek to adopt the latest technologies, the demand for sophisticated needle-based biopsy guns is likely to rise, further propelling the market forward.

## Future Outlook

The Needle-Based Biopsy Gun Market is projected to grow at a 7.32% CAGR from 2025 to 2035, driven by technological advancements, increasing cancer prevalence, and rising demand for minimally invasive procedures.

**New opportunities:**

- Development of advanced imaging integration for precision targeting Expansion into emerging markets with tailored product offerings Partnerships with healthcare providers for training and support services

By 2035, the market is expected to achieve robust growth, solidifying its position in the healthcare sector.

## Segment Insights

### By Type: Fully Automatic Biopsy Guns (Largest) vs. Semi-Automatic Biopsy Guns (Fastest-Growing)

The Needle-Based Biopsy Gun Market segment is prominently dominated by Fully Automatic Biopsy Guns, which hold the largest market share. Their advanced technology and efficiency in precision procedures make them a preferred choice among healthcare providers. In contrast, Semi-Automatic Biopsy Guns are gaining traction, appealing to users who seek a balance between automation and manual control, thereby contributing to their rapid market growth.

Biopsy Guns: Fully Automatic (Dominant) vs. Semi-Automatic (Emerging)

Fully Automatic Biopsy Guns are characterized by their ease of use and high efficiency, making them the preferred choice in many clinical settings. These devices minimize manual intervention, resulting in greater accuracy and quicker operational times. Meanwhile, Semi-Automatic Biopsy Guns are emerging as a notable alternative, providing healthcare professionals with a degree of control while still offering some automated features. This combination caters to a diverse range of preferences among practitioners, fueling their growth in the market as they adapt to various procedural requirements.

### By End-Use: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the Needle-Based Biopsy Gun Market, hospitals account for the largest share, driven by their high patient footfall and advanced infrastructure facilitating complex procedures. Diagnostic laboratories are closely following, and they play an essential role in providing rapid diagnostic services, which makes them critical in this landscape. Research institutions and ambulatory surgical centers have a smaller market presence but are vital for specialized procedures and outpatient services.

Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging)

Hospitals are the dominant segment in the Needle-Based Biopsy Gun Market due to their extensive healthcare facilities and a high volume of biopsy procedures performed. They focus on integrating advanced technologies and maintaining a broad range of biopsy guns to cater to varied patient needs. On the other hand, diagnostic laboratories emerge as a crucial segment, reflecting increased demand for accurate and timely diagnostics, often incorporating cutting-edge biopsy technologies. This shift is bolstered by the rising incidence of cancer and other diseases needing biopsy assessments, presenting diagnostic labs as an evolving and integral part of the healthcare ecosystem.

### By Product Configuration: Single-Use (Largest) vs. Reusable (Fastest-Growing)

The Needle-Based Biopsy Gun Market is segmented into Single-Use and Reusable product configurations. Single-Use devices dominate this segment due to their convenience and reduced risk of cross-contamination. They are particularly favored in clinical settings where hygiene is paramount. As a result, Single-Use devices hold the largest market share, driven by increasing patient safety regulations and healthcare providers' emphasis on simplicity in procedures. Conversely, Reusable devices are gaining traction, accounting for a smaller share but experiencing rapid growth. This surge is mainly attributed to their cost-efficiency and sustainability, appealing to institutions looking to minimize waste and economic expenditure. Growth trends for the Product Configuration segment indicate a significant shift towards Reusable devices, even as Single-Use continues to hold its ground as the preference for immediate procedures. The growing awareness of environmental impacts associated with disposable products is urging healthcare providers to adopt Reusable solutions, thereby driving their market growth. Furthermore, advancements in sterilization technologies are enhancing the appeal of Reusable devices. As healthcare systems continue to evolve, the balance between Single-Use convenience and the economic advantages of Reusable options will shape future purchasing decisions in the Needle-Based Biopsy Gun Market.

Single-Use (Dominant) vs. Reusable (Emerging)

Single-Use devices in the Needle-Based Biopsy Gun Market are characterized by their ability to provide a sterile, ready-to-use solution for each procedure, eliminating the complexities associated with reprocessing. They are widely adopted in hospitals and outpatient clinics where patient turnover is high, and efficiency is critical. The dominant position of Single-Use devices is propelled by stringent regulatory standards and a heightened focus on patient safety. On the other hand, Reusable devices represent an emerging segment, showcasing innovations that allow for effective sterilization and maintenance. The appeal of Reusable devices lies in their sustainability and long-term cost savings, gaining attention from healthcare facilities striving to adhere to eco-friendly practices while maintaining operational efficiency.

### By Needle Size: Fine Gauge (Largest) vs. Large Gauge (Fastest-Growing)

In the Needle-Based Biopsy Gun Market, the Needle Size segment showcases a diverse distribution between Fine Gauge, Medium Gauge, and Large Gauge needles. Fine Gauge needles hold the largest market share due to their enhanced precision, reducing trauma and associated complications for patients. This has positioned them favorably among healthcare providers focusing on minimally invasive techniques, reinforcing their vital role in contemporary biopsy procedures. Conversely, Large Gauge needles are emerging as the fastest-growing segment within this market, driven by a growing demand for more substantial tissue samples in complex diagnostics. Their ability to provide larger cores of tissue enhances the accuracy of pathological analysis, making them increasingly popular among oncologists and radiologists seeking reliable and comprehensive diagnostic methods as treatments evolve.

Fine Gauge (Dominant) vs. Large Gauge (Emerging)

The Fine Gauge segment is characterized by its broad acceptance in biopsy procedures, favored for its capability to minimize patient discomfort while delivering accurate results. Healthcare professionals are increasingly choosing these needles for their less invasive nature and reduced recovery times, solidifying their dominant position in the market. In contrast, Large Gauge needles are labeled as the emerging choice, driven by advancements in biopsy technology that prioritize obtaining larger tissue samples. These needles cater to specialized procedures requiring more extensive tissue analysis, thereby carving out a significant niche in diagnostics. As clinical practices evolve, both segments demonstrate unique characteristics catering to distinct medical needs, influencing overall market strategies in the biopsy field.

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America is the largest market for needle-based biopsy guns, holding approximately 45% of the global market share. The growth is driven by advanced healthcare infrastructure, increasing prevalence of cancer, and rising demand for minimally invasive procedures. Regulatory support from agencies like the FDA further catalyzes market expansion, ensuring safety and efficacy in medical devices. The United States is the primary contributor, with significant investments in R&D and a robust presence of key players such as Becton Dickinson and Company and Boston Scientific Corporation. Canada also plays a vital role, focusing on improving healthcare access and technology adoption. The competitive landscape is characterized by innovation and strategic partnerships among leading companies.

### Europe : Emerging Market with Growth Potential

Europe is the second-largest market for needle-based biopsy guns, accounting for around 30% of the global share. The region benefits from stringent regulatory frameworks that ensure high-quality medical devices, alongside increasing awareness of early cancer detection. Countries like Germany and France are leading the charge, with favorable healthcare policies promoting advanced diagnostic tools. Germany stands out as a key player, with a strong emphasis on research and development in medical technologies. The competitive landscape includes major companies like Medtronic and Hologic, which are actively expanding their product offerings. The European market is also witnessing collaborations between healthcare providers and manufacturers to enhance service delivery and patient outcomes.

### Asia-Pacific : Rapidly Growing Healthcare Sector

Asia-Pacific is witnessing rapid growth in the needle-based biopsy gun market, driven by increasing healthcare expenditure and rising cancer incidence. The region holds approximately 20% of the global market share, with countries like China and India leading the way. Government initiatives aimed at improving healthcare infrastructure and access to advanced medical technologies are significant growth drivers. China is the largest market in the region, supported by a vast population and increasing demand for diagnostic procedures. India follows closely, with a growing focus on healthcare innovation. The competitive landscape features both local and international players, including Terumo Corporation and Cook Medical, who are expanding their presence to meet the rising demand for biopsy solutions.

### Middle East and Africa : Untapped Market with Potential

The Middle East and Africa region is an emerging market for needle-based biopsy guns, currently holding about 5% of the global market share. The growth is primarily driven by increasing healthcare investments and a rising prevalence of chronic diseases, including cancer. Countries like South Africa and the UAE are focusing on enhancing their healthcare systems, which is expected to boost demand for advanced diagnostic tools. South Africa is leading the market in this region, with a growing number of healthcare facilities adopting innovative technologies. The competitive landscape is evolving, with both local and international companies, including Smith & Nephew and Stryker, looking to capitalize on the increasing demand for biopsy solutions. The region presents significant opportunities for growth as healthcare access improves and awareness increases.

## Competitive Benchmarking

The Needle-Based Biopsy Gun Market is currently characterized by a dynamic competitive landscape, driven by technological advancements and increasing demand for minimally invasive procedures. Key players such as Becton Dickinson and Company (US), Boston Scientific Corporation (US), and Hologic, Inc. (US) are strategically positioned to leverage innovation and expand their market presence. Becton Dickinson, for instance, focuses on enhancing its product portfolio through continuous research and development, while Boston Scientific emphasizes strategic partnerships to bolster its technological capabilities. Hologic, on the other hand, is concentrating on regional expansion, particularly in emerging markets, which collectively shapes a competitive environment that is both collaborative and competitive. In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and enhance supply chain efficiency. The Needle-Based Biopsy Gun Market appears moderately fragmented, with several players vying for market share. This fragmentation allows for a diverse range of products and innovations, yet the collective influence of major players like Medtronic plc (IE) and Cook Medical Incorporated (US) is significant, as they set industry standards and drive technological advancements. In August 2025, Medtronic plc (IE) announced the launch of a new needle-based biopsy gun designed to improve precision and reduce patient discomfort. This strategic move is likely to enhance Medtronic's competitive edge by addressing the growing demand for patient-centric solutions in the healthcare sector. The introduction of this innovative product not only reinforces Medtronic's commitment to advancing medical technology but also positions the company favorably against its competitors. In September 2025, Cook Medical Incorporated (US) expanded its product line by introducing a next-generation biopsy gun that integrates advanced imaging technology. This development is indicative of Cook Medical's strategy to incorporate cutting-edge technology into its offerings, thereby enhancing diagnostic accuracy. Such innovations are crucial in a market where precision and reliability are paramount, suggesting that Cook Medical is keen on maintaining its competitive advantage through technological differentiation. In October 2025, Hologic, Inc. (US) entered into a strategic partnership with a leading imaging technology firm to enhance its biopsy solutions. This collaboration is expected to facilitate the integration of advanced imaging capabilities into Hologic's biopsy guns, thereby improving procedural outcomes. The partnership underscores the importance of strategic alliances in the current market, as companies seek to combine strengths and innovate more effectively. As of October 2025, the Needle-Based Biopsy Gun Market is witnessing trends such as digitalization and the integration of artificial intelligence, which are reshaping competitive dynamics. Companies are increasingly focusing on sustainability and technological advancements to differentiate themselves. The shift from price-based competition to a focus on innovation and supply chain reliability is becoming evident, suggesting that future competitive differentiation will hinge on the ability to deliver superior technology and patient outcomes.

## Recent News & Developments

- **Q2 2024: Argon Medical Devices Announces FDA Clearance of SuperCore Advantage Biopsy Instrument** Argon Medical Devices received FDA clearance for its SuperCore Advantage Biopsy Instrument, a new needle-based biopsy gun designed for soft tissue biopsies. The device aims to improve sample quality and procedural efficiency.
- **Q1 2024: INRAD, Inc. Launches New Core Needle Biopsy Device for Breast and Prostate Applications** INRAD, Inc. announced the commercial launch of its latest core needle biopsy device, targeting breast and prostate tissue sampling. The product is now available to hospitals and diagnostic centers in the United States.
- **Q2 2024: Becton Dickinson Receives CE Mark for BD UltraCore Biopsy Device** Becton Dickinson (BD) received CE Mark approval for its BD UltraCore Biopsy Device, allowing the company to market the needle-based biopsy gun in the European Union. The device is designed for minimally invasive tissue sampling.
- **Q3 2024: Hologic Announces FDA Clearance for Brevera Breast Biopsy System with Needle-Based Gun Technology** Hologic received FDA clearance for its Brevera Breast Biopsy System, which incorporates advanced needle-based gun technology for real-time tissue acquisition and imaging during breast biopsies.
- **Q2 2024: Merit Medical Launches Temno Evolution Biopsy Device in the U.S.** Merit Medical Systems announced the U.S. launch of its Temno Evolution Biopsy Device, a single-use, needle-based biopsy gun designed to enhance procedural safety and sample quality.
- **Q1 2024: Boston Scientific Acquires Devicor Medical Products, Expanding Biopsy Device Portfolio** Boston Scientific completed the acquisition of Devicor Medical Products, a manufacturer of needle-based biopsy guns and related devices, to strengthen its position in the tissue sampling market.
- **Q2 2024: ConMed Corporation Announces Partnership with MedTech Innovations for Needle Biopsy Device Distribution** ConMed Corporation entered into a distribution partnership with MedTech Innovations to expand the reach of its needle-based biopsy guns in North America and select international markets.
- **Q3 2024: Henry Schein Launches New Line of Disposable Needle Biopsy Guns** Henry Schein introduced a new line of disposable needle biopsy guns aimed at reducing infection risk and improving procedural efficiency in outpatient and hospital settings.
- **Q2 2024: Coloplast Receives FDA 510(k) Clearance for Core Needle Biopsy System** Coloplast announced it has received FDA 510(k) clearance for its new core needle biopsy system, enabling the company to market the device for soft tissue biopsies in the United States.
- **Q1 2024: Hologic Appoints New Vice President of Biopsy Device Division** Hologic announced the appointment of a new Vice President to lead its Biopsy Device Division, overseeing the development and commercialization of needle-based biopsy guns and related products.
- **Q2 2024: Becton Dickinson Opens New Manufacturing Facility for Biopsy Devices in Ireland** Becton Dickinson inaugurated a new manufacturing facility in Ireland dedicated to the production of needle-based biopsy guns, aiming to meet growing global demand for minimally invasive diagnostic tools.
- **Q3 2024: Argon Medical Devices Secures Distribution Agreement with MedSupply for Asia-Pacific Region** Argon Medical Devices signed a distribution agreement with MedSupply to expand the availability of its needle-based biopsy guns across the Asia-Pacific region.

## Report Scope

| MARKET SIZE 2024 | 2.138(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 2.295(USD Billion) |
| MARKET SIZE 2035 | 4.651(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.32% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Becton Dickinson and Company (US), Boston Scientific Corporation (US), Medtronic plc (IE), Hologic, Inc. (US), Cook Medical Incorporated (US), Terumo Corporation (JP), Smith & Nephew plc (GB), Stryker Corporation (US), C.R. Bard, Inc. (US) |
| Segments Covered | Type, End Use, Product Configuration, Needle Size, Regional |
| Key Market Opportunities | Advancements in minimally invasive techniques enhance demand for Needle-Based Biopsy Gun Market solutions. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation and competition in the Needle-Based Biopsy Gun market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Needle-Based Biopsy Gun Market by 2035?**
A: The Needle-Based Biopsy Gun Market is projected to reach a valuation of 4.651 USD Billion by 2035.

**Q: What was the market valuation of the Needle-Based Biopsy Gun Market in 2024?**
A: In 2024, the market valuation of the Needle-Based Biopsy Gun Market was 2.138 USD Billion.

**Q: What is the expected CAGR for the Needle-Based Biopsy Gun Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Needle-Based Biopsy Gun Market during the forecast period 2025 - 2035 is 7.32%.

**Q: Which companies are considered key players in the Needle-Based Biopsy Gun Market?**
A: Key players in the Needle-Based Biopsy Gun Market include Becton Dickinson and Company, Boston Scientific Corporation, and Medtronic plc, among others.

**Q: What are the different types of biopsy guns available in the market?**
A: The market features Fully Automatic, Semi-Automatic, and Manual Biopsy Guns, with valuations of 1.895, 1.42, and 1.336 USD Billion respectively projected for 2035.

**Q: How do hospitals and diagnostic laboratories compare in terms of market share for needle-based biopsy guns?**
A: By 2035, hospitals are expected to account for 1.885 USD Billion, while diagnostic laboratories are projected to reach 1.44 USD Billion.

**Q: What is the anticipated growth in the single-use and reusable product configurations for biopsy guns?**
A: Single-use biopsy guns are projected to grow to 2.305 USD Billion, while reusable configurations are expected to reach 2.346 USD Billion by 2035.

**Q: What needle sizes are available in the Needle-Based Biopsy Gun Market?**
A: The market offers Fine Gauge, Medium Gauge, and Large Gauge needles, with projected valuations of 1.885, 1.575, and 1.191 USD Billion respectively by 2035.

**Q: What role do research institutions play in the Needle-Based Biopsy Gun Market?**
A: Research institutions are projected to contribute 0.95 USD Billion to the Needle-Based Biopsy Gun Market by 2035.

**Q: How does the market for needle-based biopsy guns evolve from 2024 to 2035?**
A: The market is expected to grow from 2.138 USD Billion in 2024 to 4.651 USD Billion by 2035, indicating robust growth.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/needle-based-biopsy-gun-market-38903*